Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Dr. Yoshiaki  Ohashi

SVice President & Full-time Audit Supervisory Board Member

Mr. Toshiaki  Itagaki

Head of Finance Supervisory Division, Chief Financial Officer & Executive Vice President

Dr. Shigehiro  Yamada Ph.D.

Head of Sustainability Department and Full-Time Audit & Supervisory Board Member

Toshiya  Sasai

Executive of Investor Relations Group & Corporate Communications Department

Dr. Osamu  Okuda

President, Chief Executive Officer & Representative Director

Mr. Shinji  Hidaka

Executive Vice President and Head of Marketing & Sales Division

Mr. Junichi  Ebihara

Executive Vice President

Mr. Tetsuya  Yamaguchi

Executive Vice President and Head of Project, Lifecycle Management & Foundation Medicine Unit

Mr. Yoshiyuki  Yano

Ms. Satoko  Shisai

Executive Vice President & Head of Digital Transformation Unit

Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd. 管理结构

管理层信息